Cannabis Law Report
JULY 18, 2022
Government minister Lord Kamall swerves this completely and diverts to a discussion on necessity for clinical trials, blaming the industry for not funding them. Debate starts with Baroness Meacher asking a question about GP prescribing.
Cannabis Law Report
MAY 31, 2022
The only psychedelic drug that is approved (outside of clinical trials) for psychiatric use—as opposed to anesthesia—through the traditional medical system is Ketamine. 2022 Active FDA Clinical Trials and State-Regulated Systems. Active FDA Regulated Clinical Trials*. On March 5, 2019, the U.S.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
MAY 29, 2022
Clinical Trials and Human Subject Protections. Before the drug approval process even begins, sponsors must initiate clinical investigations by first filing an Investigational New Drug Application (IND) with FDA. FDA’s approval of an IND will also require sufficient evidence that the trial will be safe for human subjects.
Cannabis Law Report
JUNE 9, 2022
Draft Law of Ukraine “On Amendments to Certain Legislative Acts of Ukraine Concerning the Regulation of the Circulation of Cannabis Plants for Medical, Industrial Purposes, Scientific and Scientific-Technical Activities” February 17, 2022. Draft Law of Ukraine. ARV (revised). REFERENCE to the EU acquis. explanatory note.
Cannabis Law Report
JANUARY 12, 2022
11, 2022 (GLOBE NEWSWIRE) — Gb Sciences, Inc. “We can now concentrate all our energies on advancing our plant-inspired, biopharmaceutical research and development programs into human clinical trials.” LAS VEGAS, Jan. “This is a landmark event for Gb Sciences,” said Chairman and CEO John Poss.
Cannabis Law Report
JANUARY 19, 2022
January 17, 2022. – January 17, 2022) – Psygen Industries Ltd. received a dealer’s licence issued by Health Canada on January 17, 2022 (the “ Dealer’s Licence “). received a dealer’s licence issued by Health Canada on January 17, 2022 (the “ Dealer’s Licence “).
Cannabis Law Report
JANUARY 24, 2022
Accomplished leader to oversee Goldfinch Bio’s clinical function to advance precision medicines for people living with kidney disease. Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. CAMBRIDGE, Mass.–(BUSINESS
Expert insights. Personalized for you.
52 
Let's personalize your content